Since its inception, the PTAB has gained a negative reputation among patent owners, even being referred to as “patent death squads.”[1] However, in the past year the Federal Circuit has provided a glimmer of hope for patent owners through the expansion of inter partes review (IPR) estoppel. Because of Cal. Inst. of Tech. v.
Estoppel
Uniloc v. Facebook: Federal Circuit Rules Against a Finding of Estoppel in Joinder
Earlier this month, in the precedential decision Uniloc 2017 LLC v. Facebook Inc., the Court of Appeals for the Federal Circuit (“the CAFC”) upheld the Patent Trial and Appeal Board (“the Board”) on the issue of estoppel (or lack thereof) when multiple parties file multiple, substantially similar petitions challenging a patent’s patentability.
1) The…
Review of PTAB’s Partial Institution Practice Further Clouds Scope of Estoppel
On May 22, 2017, the Supreme Court granted certiorari in SAS Institute, Inc. v. Lee, No. 16-969, 2017 WL 468440 (U.S. May 22, 2017). The issue in this appeal is whether the America Invents Act permits the Patent Trial and Appeal Board (“the Board”) to partially institute IPR proceedings (as it has been doing).…
Uncertainty Regarding the Scope of IPR Estoppel – Part II
As discussed in Part I of this article, the scope of IPR estoppel under 35 U.S.C. § 315(e) remains unclear. In Part II, we explore several approaches that courts may apply.
Specifically, the approaches considered herein contemplate the meaning of the phrase “reasonably could have raised” in the IPR estoppel statute. Clearly, Congress did not…
Uncertainty Regarding the Scope of IPR Estoppel – Part I
When the America Invents Act (“AIA”) first went into effect, it was widely believed by practitioners that the scope of the estoppel provisions under 35 U.S.C. § 315(e) was very broad. Essentially, an IPR petitioner whose petition resulted in a final written determination would be estopped from arguing in district court any §§ 102 and/or…
Petition Barred Under § 315(e)(1) Due to Art that Could Have Been “Readily Identified”
Praxair filed a first petition for inter partes review of claims 1-19 of U.S. Patent 8,846,112. The PTAB instituted review based on the first petition and concluded that all claims, except claim 9, were unpatentable. In doing so, the PTAB determined that the “providing information” step in claim 1, and “similarly-worded claims steps in other…